Condiciones de salud que ashwagandha puede ayudar a apoyar.
Ashwagandha (Withania somnifera) is among the most studied adaptogens for adrenal fatigue, acting via modulation of the HPA axis to reduce cortisol in chronically stressed individuals. Multiple randomized, double-blind, placebo-controlled trials demonstrate significant reductions in serum cortisol and perceived stress scores. It is also the pre-eminent adaptogen in Ayurvedic medicine for stress and exhaustion.
A 16-week randomized, double-blind, placebo-controlled crossover RCT in overweight men aged 40–70 found ashwagandha (21 mg of 35% withanolide glycosides daily for 8 weeks) increased testosterone by ~14.7% and DHEA-S by ~18% versus placebo. The adaptogenic herb reduces cortisol, a key suppressor of testosterone synthesis in stressed and aging men. It has been used in Ayurveda for over 3,000 years to support male vitality and reproductive health.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen used for 'Pandu Roga' (anemia). An 8-week double-blind RCT found significant improvements in hemoglobin and hematological parameters. It supports bone marrow function and reduces inflammatory burden associated with anemia of chronic disease.
Withaferin A is a potent inducer of Nrf2, a master transcription factor for antioxidant enzyme genes, upregulating SOD, catalase, glutathione peroxidase, and HO-1. This mechanism has been confirmed in multiple preclinical studies and supported by human data showing improved oxidative stress markers. Nrf2-mediated antioxidant induction is well-characterized at the molecular level.
Multiple randomized controlled trials and meta-analyses demonstrate that ashwagandha root extract significantly reduces anxiety and perceived stress scores. A 2024 meta-analysis of 9 RCTs (558 patients) showed significant reductions on the Hamilton Anxiety (HAM-A) and Perceived Stress Scale. Typical studied doses range from 240–600 mg/day of standardized extract. Its active withanolides are believed to modulate the HPA axis and reduce cortisol.
Clinical trials and traditional Ayurvedic use support ashwagandha for both rheumatoid arthritis (RA) and osteoarthritis (OA). A prospective study in 86 RA patients showed significant reductions in joint tenderness, swelling, and ESR. A 12-week RCT in knee OA found significant pain reduction within 4 weeks. Withaferin A inhibits NF-κB and AP-1 pathways active in joint inflammation.
Ashwagandha (Withania somnifera) has Ayurvedic traditional use for strength and endurance and is supported by multiple RCTs and systematic reviews showing improvements in VO2 max, muscular strength, and recovery in athletes. A 2025 systematic review of 11 systematic reviews (9,005 individuals) found promising effects on endurance and muscular strength.
Clinical studies show modest but statistically significant reductions in both systolic and diastolic blood pressure in stress-related or overweight populations. A 2012 study in 51 stressed adults showed approximately 5 mmHg systolic and 3 mmHg diastolic reduction after 60 days. Mechanisms include cortisol reduction, vasodilation via nitric oxide modulation, and anti-inflammatory effects on the vascular endothelium.
Multiple clinical studies and systematic reviews indicate ashwagandha lowers fasting blood glucose and HbA1c in diabetic and pre-diabetic subjects. Active withanolides inhibit alpha-glucosidase and DPP-4 enzymes and activate AMPK, suppressing hepatic gluconeogenesis. Evidence is promising but most trials are small and short-term.
Ashwagandha (Withania somnifera) is a well-studied Ayurvedic adaptogen whose withanolides modulate the HPA axis, lowering cortisol, reducing neuroinflammation, and supporting acetylcholine pathways. Multiple RCTs show it improves memory, attention, executive function, and reduces mental fatigue. A 2024 RCT of 59 healthy adults (225 mg/day) found significant improvements in word recall, vigilance, and reduced tension/fatigue.
Ashwagandha (Withania somnifera) has the strongest RCT evidence among natural herbs for burnout-related stress recovery. A double-blind, placebo-controlled trial (n=64) showed 27.9% reduction in serum cortisol and significant improvement on validated stress scales after 60 days of 300 mg twice daily. A 2024 systematic review and meta-analysis of multiple RCTs confirmed significant reductions in both perceived stress (PSS) and cortisol at 8 weeks.
Ashwagandha (Withania somnifera) is a foundational Ayurvedic adaptogen used for 3,000+ years for stress and nervous exhaustion. A 2024 meta-analysis of 15 RCTs (n=873, BJPsych Open) found significant reductions in anxiety (HAM-A), perceived stress (PSS), and serum cortisol vs. placebo. Withanolides modulate the HPA axis and exhibit GABAergic activity. The World Federation of Societies of Biological Psychiatry provisionally recommends it for GAD.
Ashwagandha (Withania somnifera) is a cornerstone Ayurvedic adaptogen used for thousands of years to enhance vitality and combat fatigue. Multiple RCTs show it improves VO2max, cardiorespiratory endurance, reduces fatigue, and supports mitochondrial energy production via AMPK activation and reduction of oxidative stress in mitochondria.
Several clinical trials and a double-blind pilot RCT in overweight adults found ashwagandha reduces LDL, VLDL, and triglycerides while raising HDL. Mechanistic pathways include HMG-CoA reductase inhibition and increased bile acid secretion. A 2025 PMC RCT confirmed significant reductions in LDL/HDL ratio and triglycerides.
Multiple randomized, double-blind, placebo-controlled trials demonstrate that ashwagandha root extract significantly reduces fatigue and improves energy levels in stressed and fatigued adults. A key mechanism involves HPA-axis modulation, cortisol reduction, and mitochondrial support. NIH ODS acknowledges clinical evidence for improved energy and well-being with standardized extracts.
Ashwagandha, particularly its constituent withaferin A, inhibits NF-κB signaling and suppresses pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β in both preclinical models and human trials. A 2025 PMC review confirmed clinical evidence for anti-inflammatory effects. The herb also activates Nrf2, reinforcing antioxidant defenses that counteract oxidative drivers of chronic inflammation.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen whose withanolides modulate the HPA axis, reduce nocturnal cortisol, and support circadian-aligned sleep. A PLOS ONE meta-analysis (2021) of RCTs found a standardized mean difference of -0.59 for sleep improvement versus placebo. It supports circadian balance by normalizing the cortisol-melatonin hormonal axis.
Multiple randomized, double-blind, placebo-controlled trials in humans support Ashwagandha's ability to improve memory, executive function, attention, and information-processing speed, particularly in adults with mild cognitive impairment (MCI). A 2019 systematic review of five clinical studies confirmed improvements in cognitive tasks and reaction time. The active withanolide compounds appear to act via acetylcholinesterase inhibition, antioxidant activity, and inhibition of β-amyloid aggregation. Evidence is promising but comes primarily from small, short-duration trials; large-scale long-term studies are still needed.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with multiple RCTs and a 2024 meta-analysis confirming significant cortisol reductions in stressed individuals via HPA axis modulation. It has been studied in the context of adrenal steroidogenesis disorders including non-classical adrenal hyperplasia, where it reduced multiple adrenal precursor steroids. A published case report (PMC12824993) documented that high-dose ashwagandha caused HPA axis suppression producing Cushingoid features, demonstrating its potent cortisol-modulating activity. At 300–600 mg/day standardized extract, it reduces cortisol by approximately 20–28%.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with preliminary but growing evidence for affective disorders including depression. Its withanolides modulate GABAergic and serotonergic pathways, suppress HPA axis hyperactivity, and reduce cortisol by 23–30% in RCTs. A 2018 systematic review of herbal psychiatry identified Ashwagandha as having preliminary evidence for affective disorders.
Ashwagandha (Withania somnifera) is an adaptogenic herb with clinical evidence for reducing cortisol, stress-induced food cravings, and emotional/stress-driven eating behaviors. A double-blind RCT (N=52, 8 weeks) using 300 mg twice daily found significant improvements on the Food Cravings Questionnaire and Three-Factor Eating Questionnaire versus placebo, alongside reduced cortisol. A 2025 meta-analysis of 15 RCTs confirmed significant reductions in cortisol, perceived stress, and anxiety scores.
Ashwagandha (Withania somnifera) is one of the most studied adaptogens for emotional resilience. Multiple randomized, double-blind, placebo-controlled trials demonstrate significant reductions in perceived stress, anxiety scores, and serum cortisol. Doses of 240–600 mg/day of standardized root extract for 8–12 weeks consistently outperform placebo on validated stress and anxiety scales.
Ashwagandha (Withania somnifera) is a foundational Ayurvedic rasayana used traditionally to enhance vitality and reduce fatigue. Modern RCTs demonstrate that standardized root extract significantly reduces stress-related fatigue, improves subjective energy, and enhances physical endurance and VO2 max in adults.
Ashwagandha (Withania somnifera) has been studied for psychogenic erectile dysfunction in an Ayurvedic clinical trial (AYU, 2011), and a separate RCT documented significant improvement in sexual function and testosterone in men. The 2023 MDPI dietary supplement analysis listed Withania somnifera among ingredients with one positive clinical reference for ED. Its stress-adaptogenic and testosterone-supportive properties are mechanistically relevant to erectile function.
Ashwagandha (Withania somnifera) is a foundational Ayurvedic herb used for over 3,000 years to treat male sexual dysfunction and infertility. A placebo-controlled RCT in 46 oligospermic men found 675 mg/day for 90 days produced a 167% increase in sperm count, 53% increase in semen volume, and 57% increase in motility vs. placebo. A 2026 Frontiers RCT in healthy men confirmed approximately 33–87% improvements in semen parameters.
Ashwagandha (Withania somnifera) is the most clinically validated adaptogen for HPA axis dysregulation. By reducing cortisol and stress-mediated hormonal disruption, it supports menstrual regularity and ovulation. It is used in Ayurveda for female reproductive vitality and emerging clinical studies show benefits in stress-related hormonal imbalance affecting fertility.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with RCTs demonstrating improvements in attention, memory, and executive function in healthy stressed adults and those with mild cognitive impairment. An 8-week RCT in MCI adults found significant improvements in immediate memory and attention; a 90-day RCT in stressed healthy adults found improved recall and reduced cortisol.
Ashwagandha (Withania somnifera) is an Ayurvedic Rasayana herb used for centuries as a rejuvenator and anti-aging tonic. A 2025 comprehensive review (Liverpool John Moores University, Biogerontology) documents clinical evidence for its effects on muscle strength, cardiorespiratory fitness, hormonal balance, cognitive function, telomerase activity, and inflammaging in older adults.
One of the most extensively studied adaptogens for HPA axis modulation. Multiple RCTs demonstrate that standardized root extract (300–600 mg/day of withanolide-rich extract) significantly reduces serum cortisol, ACTH secretion, and perceived stress over 8–12 weeks. A systematic review found it decreases perceived stress by 30–44% and consistently lowers cortisol in adults with self-reported high stress.
A double-blind RCT (Sharma et al., 2018, J Altern Complement Med) in 50 subclinical hypothyroid patients showed 600 mg/day ashwagandha root extract for 8 weeks significantly improved TSH (p<0.001), T3 (p=0.003), and T4 (p=0.010) versus placebo. Ashwagandha has been used in Ayurvedic medicine for hormonal disorders including thyroid imbalances for centuries.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with multiple RCTs demonstrating significant improvements in sleep quality, sleep latency, and sleep efficiency in adults with insomnia. Effects are more pronounced at doses ≥600 mg/day for ≥8 weeks.
Ashwagandha improves insulin sensitivity through multiple mechanisms including AMPK activation, PPAR-γ modulation, and inhibition of DPP-4. Clinical studies in diabetic and overweight populations have observed improvements in insulin resistance markers. A 2025 PMC review specifically addressing insulin resistance confirmed supportive preclinical and clinical evidence.
Ashwagandha (Withania somnifera) is used in Ayurvedic medicine for anemia and fatigue. Clinical evidence suggests it may improve RBC indices and reduce fatigue in iron-deficient and stressed individuals by reducing inflammatory suppression of erythropoiesis and supporting bone marrow function.
Ashwagandha (Withania somnifera) has been used in Ayurvedic medicine for over 3,000 years for menstrual irregularities and reproductive health. Scientific evidence shows it modulates the hypothalamic-pituitary-adrenal and gonadal axes, lowers cortisol, and normalizes gonadotropins. A 2025 ScienceDirect review confirms it can improve ovulation and menstrual regularity in women with hormonal imbalances.
Ashwagandha (Withania somnifera) has a 3,000-year tradition in Ayurvedic medicine as a medhya rasayana (cognitive enhancer). Multiple RCTs show improvements in memory, executive function, attention, information processing speed, and mental clarity in healthy adults and those with MCI. A 2024 PMC study found acute ingestion (400 mg) enhanced executive function and working memory for up to six hours.
Ashwagandha (Withania somnifera) is a key Ayurvedic adaptogen with multiple RCTs demonstrating significant improvements in testosterone levels, sexual function, and fertility in men. A 2019 double-blind RCT found 600 mg/day KSM-66 extract for 8 weeks significantly increased testosterone and DHEA-S in healthy men. Its withanolides reduce cortisol, which can otherwise suppress testosterone production.
Ashwagandha (Withania somnifera) is a revered Ayurvedic adaptogen used for millennia for memory, cognition, and mental vitality. A 2021 double-blind RCT (n=130 stressed adults, 300 mg/day, 90 days) found significantly improved recall memory and reduced error rates on CANTAB neuropsychological testing versus placebo. A 2024 RCT found 225 mg/day improved memory, attention, and executive function in healthy young adults.
Ashwagandha (Withania somnifera) has been studied in RCTs specifically for perimenopausal and postmenopausal women. A double-blind RCT using 300 mg twice daily for 8 weeks improved overall climacteric symptom scores in perimenopausal women. A 2025 RCT demonstrated dose-dependent reductions in menopausal symptoms, vascular dysfunction, and bone resorption markers in postmenopausal women.
Ashwagandha (Withania somnifera) is a foundational Ayurvedic adaptogen used for thousands of years to enhance mental vitality and reduce fatigue. Multiple modern RCTs confirm improvements in attention, vigilance, reaction time, memory, and mental alertness on rising.
A 2025 PMC literature review specifically on ashwagandha and metabolic syndrome confirmed it addresses multiple components: blood glucose, lipid profile, inflammation, and oxidative stress. Mechanisms include HMG-CoA reductase inhibition, PPAR-γ modulation, vasodilation, and antioxidant upregulation. Clinical evidence comes largely from trials in overweight/obese or diabetic populations.
Ashwagandha (Withania somnifera) has demonstrated mitochondrial protective effects through withanolide-mediated Nrf2 activation and reduction of mitochondrial ROS. RCTs show improvements in exercise capacity, VO₂ max, and muscle recovery, consistent with enhanced mitochondrial function. Traditionally used in Ayurveda as a rasayana for vitality and energy.
Ashwagandha (Withania somnifera) root extract has been shown in a placebo-controlled RCT to significantly reduce serum creatine kinase (a marker of exercise-induced muscle damage) and improve muscle recovery, alongside gains in strength and muscle size, in males undergoing resistance training.
RCTs demonstrate ashwagandha accelerates recovery from exercise-induced muscle damage, reduces DOMS, and lowers creatine kinase as a marker of muscle injury. A 2026 RCT in team-sport athletes found significant improvement in DOMS scores in the ashwagandha group. An 8-week RCT also showed faster muscle recovery monitored by creatine kinase normalization.
Ashwagandha (Withania somnifera) is a cornerstone of Ayurvedic medicine with extensively documented neuroprotective and adaptogenic properties. Withanolides and sitoindosides modulate the HPA axis, GABAergic signaling, and NF-κB pathways, and clinical trials show improvements in cognitive performance and stress biomarkers.
Ashwagandha (Withania somnifera) withanolides support neuroplasticity by increasing BDNF and NGF, reducing cortisol-mediated hippocampal damage, and modulating GABAergic and serotonergic systems. Clinical trials (500–600 mg/day, 8–12 weeks) show improvements in memory, executive function, and processing speed. It is a longstanding Ayurvedic adaptogen (rasayana) used to rejuvenate the nervous system.
Ashwagandha (Withania somnifera) withanolides modulate GABA-A receptors and NMDA receptors, supporting inhibitory neurotransmitter balance and reducing excitotoxicity. Multiple RCTs confirm anxiolytic and stress-reducing effects consistent with GABAergic modulation. Ayurvedic tradition has used it for centuries for nervous system support.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with multiple RCTs demonstrating significant reductions in perceived stress, anxiety, and cortisol levels. A 2024 systematic review and meta-analysis of 15 RCTs (n=873) concluded that ashwagandha formulations have beneficial effects on stress and anxiety. It has been used for over 3,000 years in Ayurvedic medicine as a rasayana herb for calming the nervous system.
Ashwagandha (Withania somnifera) is an adaptogenic Ayurvedic herb with evidence for modulating cortisol, improving thyroid function, and reducing insulin resistance—all relevant to PCOS. RCTs and systematic reviews include it among herbal interventions studied in PCOS-related metabolic and hormonal dysregulation.
Ashwagandha (Withania somnifera) root extract has been directly studied in a published 8-week, randomized, double-blind, placebo-controlled trial (Gopal et al., 2021, Journal of Obstetrics and Gynaecology Research) in 100 perimenopausal women. The ashwagandha group showed significant improvement in climacteric symptoms, quality of life, and hormonal parameters.
Ashwagandha (Withania somnifera) has been evaluated in 13+ RCTs and multiple systematic reviews demonstrating improvements in VO2max, cardiorespiratory endurance, muscle strength, and fatigue reduction in healthy individuals and athletes. A 2021 Bayesian meta-analysis and a 2025 overview of 11 systematic reviews confirmed endurance and stamina benefits. Traditionally used in Ayurvedic medicine as a rasayana (rejuvenating tonic).
A classical Ayurvedic Rasayana herb used for millennia to restore vitality and resilience after illness. Multiple RCTs demonstrate reductions in cortisol, fatigue scores, and stress markers. A systematic review of 13 RCTs confirmed benefits on fatigue, stress resilience, and physical recovery outcomes.
Ashwagandha (Withania somnifera) is classified as an adaptogen with multitarget effects on the neuroendocrine-immune system relevant to post-viral recovery, including stress hormone modulation, immune enhancement, and anti-inflammatory effects. It is listed among key adaptogens for COVID-19 post-viral recovery by authoritative herbal medicine reviews. RCTs demonstrate significant improvements in fatigue, sleep quality, and stress resilience.
Ashwagandha is an Ayurvedic adaptogen increasingly included in postnatal formulas for postpartum stress, fatigue, and mood support. Clinical evidence includes multiple RCTs showing reduction in perceived stress and cortisol. Expert postnatal supplement guides specifically list ashwagandha for postpartum mood changes and adrenal support.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen whose withanolides modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol. Since chronic cortisol elevation suppresses GnRH and downstream LH/FSH, cortisol reduction can restore the ovulatory signaling needed for progesterone production. A 2025 randomized double-blind placebo-controlled trial in 60 perimenopausal women (300 mg extract twice daily, 56 days) showed significant increases in serum progesterone and estradiol and reductions in FSH and LH versus placebo (p<0.001). Evidence is strongest for stress-mediated hormonal disruption.
Ashwagandha (Withania somnifera) has been used in Ayurvedic medicine for joint inflammation for millennia. Withanolides inhibit NF-κB and pro-inflammatory cytokines relevant to RA. Clinical trials have shown reduced pain and inflammation in arthritis patients; animal studies confirm anti-arthritic activity in collagen-induced arthritis models.
Ashwagandha (Withania somnifera) root extract has been specifically shown to reduce wake after sleep onset (WASO) in multiple RCTs. A 2020 double-blind RCT (n=144, 600 mg/day, 6 weeks) found significant improvements in WASO (p<0.05), sleep efficiency (p<0.01), and total sleep time (p<0.001) versus placebo. A 2021 meta-analysis of 5 RCTs (n=400) confirmed a significant overall sleep benefit (SMD −0.59, 95% CI −0.75 to −0.42).
Ashwagandha (Withania somnifera) root extract has been used in Ayurvedic medicine for millennia as a Rasayana (rejuvenator) and sleep promoter. Multiple recent double-blind RCTs demonstrate significant improvements in sleep onset latency, total sleep time, and sleep efficiency, with the NIH ODS confirming this evidence.
Ashwagandha (Withania somnifera) root extract has significant scientific evidence for improving sleep quality. A 2021 systematic review and meta-analysis of 5 RCTs (n=400) found a small but significant effect on overall sleep (SMD −0.59; 95% CI −0.75 to −0.42), with greater effects at doses ≥600 mg/day and treatment ≥8 weeks. It modulates GABA-A receptors (ρ1 subtype) and histamine H3 receptors. In Ayurvedic medicine, it has been used for centuries as a nervine tonic.
One of the most extensively studied adaptogens for stress. Multiple double-blind, placebo-controlled RCTs demonstrate significant reductions in perceived stress scores and serum cortisol. Active withanolides modulate the HPA axis and GABAergic signaling. Used in Ayurvedic medicine for over 3,000 years as a rasayana (rejuvenating tonic).
Multiple double-blind RCTs using standardized root extracts (300–600 mg/day of withanolide-standardized preparations) have demonstrated increases in serum testosterone of 14–17% in healthy and infertile men. The proposed mechanism involves cortisol/HPA-axis modulation and upregulation of LH secretion. Systematic reviews identify ashwagandha as among the best-evidenced herbal testosterone supporters.
Ashwagandha (Withania somnifera) root extract has been shown in a randomized controlled trial to normalize serum T3, T4, and TSH in subjects with subclinical hypothyroidism. Active withanolide glycosides are thought to stimulate thyroid secretory function via the hypothalamic-pituitary-thyroid axis. It is also traditionally recommended in Ayurvedic medicine for thyroid imbalances.
Ashwagandha (Withania somnifera) has been studied in multiple RCTs for metabolic effects including lipid lowering. Clinical trials and a meta-analysis show significant reductions in LDL, total cholesterol, and triglycerides. Used in Ayurvedic medicine as a rasayana (rejuvenating tonic) for centuries.
Ashwagandha (Withania somnifera) is a primary Ayurvedic adaptogen with immunomodulatory properties including NK cell activation and T cell function enhancement. Modern clinical studies confirm immune cell activity enhancement. Withanolides, its primary bioactives, have shown antiviral activity against HIV and influenza in vitro.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with documented traditional use specifically for supporting adrenal health in Addison's disease contexts. Its withanolides modulate the HPA axis and ACTH signaling, and Ayurvedic texts and modern naturopathic practitioners document its use in managing Addison's disease as an adjunct. Clinical studies show HPA axis modulation, though RCTs specifically in Addison's disease patients are lacking.
Ashwagandha is documented in Ayurvedic medicine as a treatment for bronchitis and asthma. A 2025 preclinical biorxiv study showed withaferin A reduces pulmonary eosinophilia and IL-25 in a mouse allergic airways model. No human RCTs for asthma have been published; the evidence base remains traditional and preclinical.
Ashwagandha has traditional Ayurvedic use in conditions resembling autoimmune diseases, and preclinical data shows reduction of autoreactive T cells and inflammatory cytokines in animal models of RA and lupus. However, clinical evidence in human autoimmune populations is limited. Its immunostimulant effects also create theoretical risk of aggravating certain autoimmune diseases.
Ashwagandha has a documented history of use in Ayurvedic medicine for epilepsy, listed consistently in traditional texts and modern Ayurvedic formulations. The NIH LiverTox database and MSKCC integrative medicine resource both acknowledge traditional Ayurvedic use for epilepsy. Proposed mechanisms involve GABAergic modulation, but human clinical trial evidence is absent.
Ashwagandha (Withania somnifera) is proposed to support hair growth indirectly by reducing cortisol levels (high cortisol is linked to telogen effluvium) and potentially enhancing scalp blood flow. Studies confirm it reduces stress and cortisol; the proposed connection to hair growth via stress modulation has mechanistic plausibility. Direct RCT evidence for hair growth outcomes is lacking.
Ashwagandha (Withania somnifera) is a major Ayurvedic adaptogen with anti-stress and cortisol-lowering properties. Since chronic elevated cortisol is a known trigger for telogen effluvium, ashwagandha's stress-reduction effects are mechanistically relevant to stress-related hair loss. It is listed among hair-health ingredients in authoritative Ayurvedic and integrative medicine sources.
Ashwagandha (Withania somnifera) is a core Ayurvedic herb traditionally indicated for sciatica as a Vata-pacifying adaptogen. It is used to reduce inflammation and irritation in sciatic nerves, strengthen back muscles and spine, and rejuvenate neural tissue. Scientific evidence for sciatica is absent in clinical trials; evidence derives from Ayurvedic textual sources and traditional practice.
Volver